1. Home
  2. MNPR vs GLAS Comparison

MNPR vs GLAS Comparison

Compare MNPR & GLAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$70.28

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Logo Glass House Brands Inc. Subordinate Voting Shares

GLAS

Glass House Brands Inc. Subordinate Voting Shares

N/A

Current Price

$1.23

Market Cap

504.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MNPR
GLAS
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
504.2M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MNPR
GLAS
Price
$70.28
$1.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
3
Target Price
★ $130.17
$6.67
AVG Volume (30 Days)
127.0K
★ 2.2M
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 54.99
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$0.52
Revenue Next Year
N/A
$20.48
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$50.07
$1.06
52 Week High
$124.82
$12.70

Technical Indicators

Market Signals
Indicator
MNPR
GLAS
Relative Strength Index (RSI) 42.77 24.25
Support Level $66.88 $1.06
Resistance Level $75.33 $2.81
Average True Range (ATR) 4.74 0.32
MACD 0.73 0.09
Stochastic Oscillator 51.81 8.50

Price Performance

Historical Comparison
MNPR
GLAS

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

About GLAS Glass House Brands Inc. Subordinate Voting Shares

Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.

Share on Social Networks: